Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients.

EGFR-TKI had become the first-line treatment of metastatic NSCLC and widely used in clinical. It was reported that there was difference in response rate between NSCLC patients with or without EGFR mutation. However, there was no relevant studies about the difference in clinical response among patients with different kinds of EGFR mutation.